Iovance Biotherapeutics downgraded by Goldman with a new price target
$IOVA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Goldman downgraded Iovance Biotherapeutics from Neutral to Sell and set a new price target of $1.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/15/2025 | $1.00 | Neutral → Sell | Goldman |
| 5/16/2025 | $2.00 | Buy → Neutral | UBS |
| 5/12/2025 | Buy → Hold | Truist | |
| 5/9/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 10/24/2024 | $17.00 | Buy | UBS |
| 7/29/2024 | $19.00 → $10.00 | Overweight → Neutral | Piper Sandler |
| 11/20/2023 | $12.00 | Buy | Goldman |
| 9/18/2023 | $40.00 → $18.00 | Overweight | Barclays |
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Onc
SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2025 financial results and corporate updates on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on August 7, 2025, at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/cgjzdfym. The live and archived webcast can be accessed i
SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on July 17, 2025 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 138,190 shares of Iovance's common stock to 20 new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13, 202
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
3 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
3 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
SAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Corleen Roche as Chief Financial Officer (CFO), effective August 6th, 2025. "I am pleased to welcome Corleen to Iovance at such an important stage in our first commercial launch," said Frederick G. Vogt, Ph.D., J.D., Interim Chief Executive Officer, President and General Counsel. "Corleen's experience in executive financial leadership roles and multiple product launches will be in
SAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Marc. R Theoret, M.D. to assume the newly created position of Senior Vice President, Regulatory Strategy, where he will focus on clinical regulatory strategy for Iovance's pipeline. Effective immediately, Dr. Theoret will report to Dr. Raj K. Puri, M.D., Ph.D., Chief Regulatory Officer. For more than 15 years, Dr. Theoret held various roles in the United States Food and Drug Administrat
Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum
SAN CARLOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2025 financial results and corporate updates on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on August 7, 2025, at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/cgjzdfym. The live and archived webcast can be accessed i
SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wi5b4tnt. The live and archived webcast can be accessed in the Investors sectio
SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full year 2024 financial results and corporate updates on Thursday, February 27, 2025. Fourth Quarter and Full Year 2024 Audio WebcastManagement will host a live audio webcast to discuss these results and provide a corporate update on February 27, 2025 at 4:30 p.m. EST. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/hw2g9axf/. Upcoming
Goldman downgraded Iovance Biotherapeutics from Neutral to Sell and set a new price target of $1.00
UBS downgraded Iovance Biotherapeutics from Buy to Neutral and set a new price target of $2.00
Truist downgraded Iovance Biotherapeutics from Buy to Hold
For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B
10-Q - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
SCHEDULE 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)
SC 13D/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)